For CEOs, general counsels and CTOs, the question is no longer whether patents are important. The question is whether the company has an intentional strategy to identify, capture, and deploy intellectual property in alignment with product and company goals.
Digital health companies are building basic healthcare infrastructure. AI-based clinical decision support, remote monitoring platforms, digital therapeutics and data orchestration systems are no longer experimental. For many companies, these AI systems are the product. When technology is core to business value, it must be protected as such.
Yet many digital health companies still view patenting as a future consideration, something to be addressed after product-market fit or in the next funding round. This approach creates more and more risks. In today’s AI-driven healthcare market, patents are not optional legal artifacts. It is a strategic business tool that protects company valuation, strengthens defensibility, shapes competitive leverage, and reduces downside exposure.
The move from code to capability
Historically, many digital health companies subscribed to a first-to-market or fastest-to-market strategy that relied on speed, trade secrets and execution to stay ahead of the curve and minimized or ignored patent protection. The assumption was that the company’s products and competitive and technological landscapes would evolve too quickly for patent protection to be worthwhile. This assumption is no longer valid.
Patents are particularly suited to protecting this layer of innovation. Unlike copyrights, which protect specific source code, or trade secrets, which only protect against misappropriation, patents protect functional capabilities. They establish enforceable rights over how a system works, not just how it is written.
Well-designed digital health patents protect system-level functionality. This includes how data is ingested and normalized, how models are trained or refined in regulated environments, how results are validated or constrained, and how decisions are operationalized in clinical settings. These capabilities are often the true competitive advantage.
Why AI is raising the stakes
AI has increased both the value of innovation and the risk of exposure. On the one hand, AI enables rapid iteration and differentiation. On the other hand, it speeds up competitive replication. A feature that took years to develop can now be approached in months by a well-funded competitor using similar models and public research.
Patents create a counterbalance. They establish enforceable limits around what competitors can and cannot do, even if they independently build similar systems. This is particularly important in healthcare AI, where multiple companies often tackle the same clinical or operational problems using overlapping technical approaches.
There is also a regulatory dimension. AI in healthcare is increasingly scrutinized by regulators, payers and corporate clients. Patents can serve as objective proof of technical novelty and investment. They indicate that a company has built something significantly different, not just assembled off-the-shelf components.
Patents and data strategy go hand in hand
A common misconception is that data alone is the gap. Although proprietary data is valuable, data rights are fragile. Access may be lost, licenses may terminate, and regulatory interpretations may change. Patents provide sustainability where access to data may not be possible.
In AI-based digital health platforms, patents can protect how the data is used, not just the data itself. This includes methods for training models on sensitive data while preserving privacy, bias mitigation or explainability techniques, and architectures that enable models to work within healthcare compliance frameworks.
For companies navigating HIPAA, state privacy laws, and emerging AI governance regimes, this is critical. A patent portfolio aligned with your data strategy can strengthen compliance by design and reduce reliance on a single data source.
Defensive value and reality of litigation
Digital health is no longer a litigation-free industry. Patent claims are increasing, particularly as the industry matures and releases accelerate. Patent litigation has grown significantly in the field of medical technology from 2020 to 2025. Companies without patents are exposed. They have little leverage to counter claims and often face binary outcomes: settle or litigate from a position of weakness.
A thoughtful patent portfolio changes this dynamic. Even a modest number of high-quality patents can deter opportunistic claims and create leverage in litigation. This is not about being procedural. It’s about risk management.
For general counsel, patents also promote cleaner diligence and smoother transactions. Acquirers and investors increasingly expect to see patent coverage around core platform functionality, particularly when AI is central to the value proposition. The absence of patents raises questions about defensibility which may impact valuation.
Timing matters more than ever
Patent strategy is not something that can be implemented on a large scale. Filing a request too late may result in the complete loss of your rights. Public disclosures, customer demonstrations, regulatory submissions and even investor presentations can create prior art that limits what can be protected.
The most effective patent programs start sooner than many companies expect. However, this does not mean filing dozens of applications prematurely. This means identifying fundamental technical concepts early and protecting them before they are made public.
For CTOs, this requires coordination between engineering and legal teams. Engineers need to understand that patents are not intended to slow down innovation. It’s about capturing it. For CEOs, this means treating patents as a business decision, not a purely legal one.
Patents as a strategic signal
Beyond protection, patents send a signal to the market. They demonstrate long-term thinking, technical depth and seriousness about defensibility. In competitive sales for companies, especially to health systems and payers, this signal matters. This reassures customers that the platform they adopt is not easily moved.
In the AI context, where skepticism about commodification is growing, patents help distinguish truly differentiated platforms from those that are not. They talk about how the technology works and why it’s difficult to replicate.
A practical way to follow
Not every digital health company needs a large patent portfolio, but all digital health companies should make intentional decisions regarding patents. Digital health companies should:
- Identify what truly differentiates their platform at a business level.
- Focus on system-level features and innovations (e.g., how a recommendation AI engine works), rather than surface-level features (e.g., what the recommendation AI engine does from an end-user perspective), that were designed, developed, or integrated to bring these differentiators to life.
- Align patent strategy with data strategy, regulatory posture and product roadmap.
- File early enough to preserve options, but wisely enough to avoid noise.
- Most importantly, integrate thinking about patents into broader governance of AI and technology. In a world where AI is at the heart of healthcare innovation, patents are no longer optional. They are part of the infrastructure of a sustainable digital health business.
- Encourage developers and engineers to capture instances and details of solving a technology problem during the software development lifecycle.
For companies building the next generation of healthcare platforms, the question is simple. If the technology is worth developing, it is worth protecting.